The Transcatheter Pulmonary Valve (TPV) is an artificial heart valve made by sewing a bovine jugular venous valve to a small metal frame. A transcatheter pulmonary valve is a thin, hollow, long tube (catheter) system that delivers a transcatheter pulmonary valve to the heart without open heart surgery while the heart is beating.
The transcatheter pulmonary valve is first compressed into a balloon at the tip of the delivery catheter and delivered into the body, then the balloon inflates at the pulmonary heart valve to open the transcatheter pulmonary valve, and the catheter is immediately removed from the body. New pulmonary valve. A transcatheter pulmonary valve used in patients who are born with a defect in the heart and whose conduits are not functioning.
Transcatheter pulmonary valves help delay the time a patient needs additional open heart surgery. Transcatheter pulmonary valve also reduces the total number of open heart surgeries a patient needs in his or her lifetime.
Get a sample copy of the report @ https://www.persistencemarketresearch.com/samples/14152
The transcatheter pulmonary valve (TPV) market is driven by an increasing prevalence of comorbidities such as diabetes and cardiovascular disease, coupled with an increased incidence of congestive heart disease (CHD) in different patient age groups. I have. Transcatheter pulmonary valves have been shown primarily to extend the functional life of the RV-PA conduit, restore the capacity of the pulmonary valve, and alleviate conduit stenosis without inducing regurgitation in the patient, transcatheter pulmonary artery over a predicted period. Favor the valve market.
In addition, valves that are effective in prolonging open heart surgery, backed by strong clinical benefits in three clinical trials, are expected to boost revenue growth in the transcatheter pulmonary valve market during the prediction interval. However, the low target population of treatment and pacific pace adoption in both developing and developed countries could adversely affect revenue growth in the transcatheter pulmonary valve market over the projected period.
The transcatheter pulmonary valve (TPV) market is divided based on product type, end user and region.
Based on product type, the transcatheter pulmonary valve (TPV) market is divided as follows:
- valve
- Delivery system
Based on the end user, the transcatheter pulmonary valve (TPV) market is divided as follows:
- hospital
- Hospital with more than 500 beds
- Hospital with 500-300 beds
- Bed hospital less than 299
- Heart disease center
Request customization of this report @ https://www.persistencemarketresearch.com/request-customization/14152
The transcatheter pulmonary valve (TPV) market is changing due to the promising clinical development of new technologies in the pipeline and the growing demand for minimally invasive treatments among healthcare professionals and patient groups. The first transcatheter pulmonary valve (TPV) was introduced by Medtronic plc in 2010 under the Humanitarian Device Exemption (HDE). This is regulatory approval for the treatment of less than 4,000 US patients annually.
In late 2015, Medtronic plc received a Pre-Market Approval (PMA) from the US Food and Drug Administration (FDA) company’s device Melody, based on significant clinical evidence from three clinical trials.
Geographically, the transcatheter pulmonary valve (TPV) market is divided into regions. North America, Latin America, Europe, Asia Pacific, Japan, Middle East, Africa. The North American and European regions are projected to maintain their lion’s share over the forecast period. Advanced medical infrastructure and highly available healthcare professionals are expected to drive demand for transcatheter pulmonary valve (TPV) during the forecast period in the above regions.
The Asia Pacific region is expected to become a moderately growing regional market. Growing medical facilities, heightened health awareness, and a fostering regulatory environment are driving demand for transcatheter pulmonary valve (TPV) primarily in the region.
For players on the Transcatheter Pulmonary Valve (TPV) market, Medtronic plc. , Edwards Lifesciences Corporation, VENUS MEDTECH and more.
Pre-book now for exclusive analyst support @ https://www.persistencemarketresearch.com/checkout/14152
About us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – www.persistencemarketresearch.com